<DOC>
	<DOCNO>NCT02155335</DOCNO>
	<brief_summary>This study design determine whether ulcerative colitis participant prefer delivery golimumab via prefilled syringe Smartject™ device .</brief_summary>
	<brief_title>Preference Prefilled Syringe Smartject™ Device Delivering Golimumab Participants Suffering From Moderate-to-severe Ulcerative Colitis ( MK-8259-027 )</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Antitumor necrosis factor ( antiTNF ) naive participant diagnosis moderatetosevere ulcerative colitis . Mayo clinic score &gt; = 6 , include endoscopic subscore &gt; =2 ; Previous conventional therapy period least 3 month aminosalicylates least 3 month corticosteroid 6mercaptopurine ( 6MP ) azathioprine ( AZA ) , unless participant intolerant , contraindication treatment ; AntiTNF experience participant establish diagnosis moderatetosevere ulcerative colitis , either respond partially respond treatment Remicade ( infliximab ) . The participant must also meet follow criterion prior initiate firstline antiTNF treatment : Mayo score ≥ 6 , include endoscopic subscore ≥ 2 ; previous conventional therapy least 3 month aminosalicylates least 3 month corticosteroid 6mercaptopurine ( 6MP ) azathioprine ( AZA ) , unless participant intolerant medical contraindication therapy ( document ) ; Sexually active woman childbearing potential must agree use medically accept method contraception receive study drug 6 month stop study drug Has history prior selfinjection reason ; Has concomitant use biologic agent ; Has active tuberculosis ( TB ) within 12 month prior first injection suspect latent TB indicate positive tuberculin skin test . Has active clinical nontuberculous mycobacterial infection opportunistic infection within 6 month prior first injection ; Has active infection and/or serious infection within 6 month prior first study drug administration ; Has live viral bacterial vaccination within 3 month prior first study injection Bacillus CalmetteGuerin vaccination within 12 month prior first study drug injection ; Has evidence heart failure New York Heart Association class 34 ; Has history demyelinate disease multiple sclerosis optic neuritis ; Has history systemic lupus erythematosus ; Has history lymphoproliferative disease , unknown malignancy history malignancy within prior 5 year , exception nonmelanoma skin cancer treat evidence recurrence ; Has active hepatitis B infection ; Has allergy sensitivity golimumab excipients ; Is pregnant breast feeding ; Is sensitive latex .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>